Helping to improve your quality of life.

Ampio Pharmaceuticals is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. We are developing compounds that serve significant medical needs in osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases through an innovative discovery and development platform.

Pharmaceutical Product Pipeline

Ampio has advanced its lead development assets into late-stage, pivotal clinical trials in the US.

Learn More About:

Osteoarthritis of the Knee

Ampio is developing Ampion™ for the treatment of osteoarthritis of the knee.


Diabetic Macular Edema

Ampio is developing Optina™ for the treatment of Diabetic Macular Edema.

AMPE Stock Quote - delayed
Last Change
AMPE 5.68 Down 0.06 (1.09%)

Ampio News

04/22/2014 | Press Release

Luoxis Awarded Health Canada Approval for RedoxSYSTM Diagnostic System

04/21/2014 | Press Release

Ampio Pharmaceuticals’ Vyrix Files Registration Statement for Proposed Initial Public Offering

04/10/2014 | Press Release

Ampio Pharmaceuticals’ Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane™ in Canada and Other Territories to Broaden its International Footprint

» See all Ampio news